Fig. 1: CONSORT diagram.

^aOther treated patients include patients with ROS1⁺ non-NSCLC, ALK gene fusions and any gene fusions with discordant results between local FISH test and central laboratory test. ^bAt data cutoff, 42 patients remained on treatment (29 in the TRK TKI-naive cohort and 13 in the TRK TKI-pretreated cohort). The most common reason for discontinued treatment was disease progression (41 patients). ^cNine NTRK⁺ patients in phase 1 (five in the TRK TKI-naive cohort and four in the TRK TKI-pretreated cohort). ^dEfficacy analysis set includes treated patients with at least 6 months of follow-up after the first post-baseline scan.